Head Innovators Selected for the Galien Prize 2019

Published on: 

The Galien Foundation has selected nominees for its award, which recognizes those therapies and technologies with the greatest potential impact on human health.

The Galien Foundation has released the list of nominees for its 2019 award, which recognizes the most innovative and important biomedical therapies and products approved within the past five years.

"We are blessed to live in a time of exciting scientific, medical, and technological advances that promise a revolution in cures, treatments, and tools for patients everywhere,"" said Dr.Sue Desmond-Hellmann, chair of the Prix Galien USA Awards Committee and CEO of the Bill & Melinda Gates Foundation. "The 2019 nominees demonstrate this incredible potential across multiple platforms and reflect the abundance of new science that underpins the Galien Foundation's mission to improve the human condition."

This year’s nominees include:

·The first FDA-approved drugs using RNA interference technology and targeted mutation gene therapy

·The first of a new line of 'tissue agnostic' cancer-fighting drugs

·A new class of female contraceptives designed for use in resource-limited settings

·Novel inhalation devices that enhance dosing accuracy against major chronic conditions such as asthma and COPD

·The first FDA-approved therapy for endometriosis pain in more than a decade

·The first in a new class of anti-epileptic drugs

·The first prescription product derived from the cannabis plant

·The first prescription digital therapeutic to address the opioid abuse crisis through interactive engagement between patient and clinician

Among the nominees for best biotech product of 2019 are:

Amgen’s Aimoviq (erenumab-acce)

Portola’s Andexxa

Regeneron and Sanofi’s Dupixent


Stemline Therapeutics’ ELZONRIS

Lilly’s Emgality


Genentech’s Hemlibra

Spark Therapeutics’ LUXTURNA

Ainylam’s ONPATTRO

BioMarin’s Palynziq

GlaxoSmithKline’s SHINGRIX

Janssen’s TTREMFYA


Nominees for best pharmaceutical product include The Population Council’s ANNOVERA, Pfizer’s DAURISMO, Janssen’s ERLEADA, and AstraZeneca’s LUMOXITI.

Nominees for best medical product of the year include Lynch Biologics’ Augment Injectable Bone Graft, Boston Scientific’s AXIOS stent, and Abbott’s FreeStyle Libre 14-day flash glucose monitoring system.

For a full list of the nominees, please see the Foundation’s Press Release.

Winners will be announced during the Prix Galien USA Awards Ceremony on October 24, 2019 at the American Museum of Natural History in New York City.Registration to attend the 2019 Prix Galien Awards Ceremony can be accessed at http://register.prix-galien-usa.com